The evidence for effectiveness of heterologous priming of COVID-19 vaccine is very limited. Here, we studied eighteen participants who received heterologous vaccination regimen of AstraZeneca’s ChAdOx1-nCov-19 followed by inactivated whole virion BBV152. Heterologous group participant doesn’t report any adverse event following immunization and demonstrated high humoral and neutralizing antibody response.
All Keywords
【저자키워드】 SARS-CoV-2, Covaxin, Covishield, immunogenecity, Heterologous regime,
【저자키워드】 SARS-CoV-2, Covaxin, Covishield, immunogenecity, Heterologous regime,